carfilzomib

Known as: (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide 
An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma… (More)
  • figure 1
  • table 2
  • table 1
  • table 4
  • table 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies… (More)
  • figure 1
  • table I
  • table III
  • table IV
  • table II
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Carfilzomib is a proteasome inhibitor in clinical development that primarily targets the chymotrypsin-like (CT-L) subunits in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and structurally… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?